Panelists discuss how the relapsed/refractory chronic lymphocytic leukemia treatment landscape evolved significantly in 2024 with expanded Bruton tyrosine kinase inhibitor options, growing real-world ...

Recent years have brought more targeted agents to the frontline treatment for patients with chronic lymphocytic leukemia. Strides have been made for the frontline treatment of patients with chronic ...

Seema Bhat, MD, comments on the prevalence of racial and ethnic disparities in the diagnosis and treatment of chronic lymphocytic leukemia. Invoking the multiple factors that contribute to differences ...

Seema Bhat, MD, poses the past era of chemoimmunotherapy against the new age of Bruton tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia. Noting the often deleterious side ...